Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

  Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

 Presentations to be Webcast on June 17, 2014 at 4:05 P.M. ET and June 25 at
                                10:30 A.M. ET

Wells Fargo Healthcare Conference 2014 JMP Securities Healthcare Conference
2014

Business Wire

WATERTOWN, Mass. -- June 10, 2014

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused
biotechnology company dedicated to creating small molecule drugs in the
infectious disease field, today announced that Jay R. Luly, Ph.D., President
and Chief Executive Officer, will present a corporate overview on Tuesday,
June 17, 2014, at 4:05 p.m. ET during the Wells Fargo 2014 Healthcare
Conference in Boston and on Wednesday, June 25, 2014 at 10:30 a.m. ET during
the JMP Securities 9^th Annual Healthcare Conference in New York.

A live webcast and replay of each presentation can be accessed by visiting the
“Calendar of Events” section on the “Investors” page of Enanta’s website at
www.enanta.com. A replay of each webcast will be available following the
presentation and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology
company that uses its robust chemistry-driven approach and drug discovery
capabilities to create small molecule drugs in the infectious disease field.
Enanta is discovering, and in some cases developing, novel inhibitors designed
for use against the hepatitis C virus (HCV). These inhibitors include members
of the direct acting antiviral (DAA) inhibitor classes – protease (partnered
with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as
well as a host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of antibiotics,
called Bicyclolides, for the treatment of multi-drug resistant bacteria, with
a focus on developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus) infections.

Contact:

Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
 
Press spacebar to pause and continue. Press esc to stop.